Market Overview - The Shanghai Composite Index fell by 0.30% on September 19, with 16 industries rising, led by coal and non-ferrous metals, which increased by 1.97% and 1.19% respectively [2] - The automotive and pharmaceutical industries experienced the largest declines, with drops of 1.94% and 1.41% respectively [2] Capital Flow Analysis - The main capital outflow from the two markets totaled 58.733 billion yuan, with 8 industries seeing net inflows [2] - The non-ferrous metals industry had the highest net inflow, amounting to 872 million yuan, while the media industry followed with a net inflow of 692 million yuan and a daily increase of 0.49% [2] - A total of 23 industries experienced net capital outflows, with the computer industry leading at 10.723 billion yuan, followed by the automotive industry with 7.929 billion yuan [2] Pharmaceutical Industry Performance - The pharmaceutical industry saw a decline of 1.41% with a total net capital outflow of 7.085 billion yuan [3] - Out of 474 stocks in the pharmaceutical sector, 65 stocks rose while 405 stocks fell, including one stock hitting the daily limit down [3] - The top three stocks with the highest net inflow in the pharmaceutical sector were: - Borui Pharmaceutical with a net inflow of 130 million yuan - Mindray Medical with 75.259 million yuan - Micron Technology with 73.759 million yuan [3][4] Capital Outflow in Pharmaceutical Sector - The stocks with the largest capital outflows included: - China National Pharmaceutical with a net outflow of 406 million yuan - Furuya Shares with 342 million yuan - Xingqi Eye Medicine with 188 million yuan [5] - Other notable outflows included: - Hengrui Medicine with a net outflow of 172 million yuan - Celgene Medical with 158 million yuan [5][6]

Core Viewpoint - On September 19, Xingqi Eye Pharmaceutical experienced a decline of 5.1%, with a stock price of 67.96 yuan per share, a trading volume of 872 million yuan, a turnover rate of 6.64%, and a total market capitalization of 16.674 billion yuan [1] Company Overview - Xingqi Eye Pharmaceutical Co., Ltd. is located in Shenyang, Liaoning Province, and was established on March 24, 1977, with its listing date on December 8, 2016 [1] - The company's main business involves the research, production, and sales of ophthalmic drugs, with revenue composition as follows: eye drops 82.15%, gel/eye ointment 16.70%, and others 1.15% [1] Shareholder Information - Southern Fund's Southern CSI 500 ETF (510500) is among the top ten circulating shareholders of Xingqi Eye Pharmaceutical, having increased its holdings by 764,100 shares in the second quarter, totaling 2.5163 million shares, which represents 1.34% of the circulating shares [2] - The estimated floating loss for the ETF today is approximately 9.1846 million yuan [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a latest scale of 113.438 billion yuan, and has achieved a year-to-date return of 27.4% [2] Fund Performance - The Southern Big Data 300 Index A (001420) holds 47,800 shares of Xingqi Eye Pharmaceutical, accounting for 0.93% of the fund's net value, ranking as the seventh largest holding [3] - The estimated floating loss for this fund today is about 174,300 yuan [3] - The Southern Big Data 300 Index A was established on June 24, 2015, with a latest scale of 2.17 billion yuan, and has achieved a year-to-date return of 37% [3]

Core Viewpoint - The company emphasizes its competitive advantage with the only approved eye medication for delaying myopia progression in children, while maintaining stable pricing despite market competition and potential new entrants [1] Group 1 - The company has the first and only officially approved eye medication in China for delaying myopia progression in children, known as Xingqi® Meiyoupin® [1] - Two additional concentrations of atropine eye drops (0.02% and 0.04%) have completed phase III clinical trial summary reports, which will enhance the company's myopia prevention product matrix upon their market launch [1] - Currently, the approved product is not included in centralized procurement, allowing the company to maintain stable pricing in the competitive market [1]

Group 1 - The chemical pharmaceutical sector experienced a decline of 0.2% on September 17, with Warner Pharmaceuticals leading the drop [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] - Notable gainers in the chemical pharmaceutical sector included ST Tian Sheng, which rose by 4.97% to a closing price of 5.28, and Bai Li Tian Heng, which increased by 4.08% to 372.00 [1] Group 2 - Warner Pharmaceuticals saw a significant decline of 9.22%, closing at 57.92, contributing to the overall downturn in the sector [2] - Other notable decliners included Anglikang, down 4.53% to 41.28, and Guangsheng Tang, down 4.40% to 111.91 [2] - The sector experienced a net outflow of 1.541 billion yuan from major funds, while retail investors saw a net inflow of 1.516 billion yuan [2][3] Group 3 - Major fund inflows were observed in companies like Heng Rui Pharmaceutical, which had a net inflow of 3.43 million yuan, while retail investors showed a net outflow of 58.13 million yuan [3] - The top net inflows from retail investors were seen in Hai Zheng Pharmaceutical, with 34.03 million yuan, and Hua Yuan Biological, with 30.05 million yuan [3] - The overall trend indicates a shift in investment dynamics within the chemical pharmaceutical sector, with retail investors showing resilience despite major fund outflows [3]

Core Viewpoint - The report from Dongfang Securities indicates that Xingqi Eye Medicine achieved a net profit attributable to shareholders of 335 million yuan in the first half of 2025, representing a year-on-year increase of 97.8% [1] - The strong performance is attributed to robust growth in core products such as atropine and cyclosporine eye drops, along with improved profit margins due to an optimized product mix [1] Financial Performance - The net profit excluding non-recurring items reached 331 million yuan, reflecting a year-on-year increase of 96.3% [1] - The gross profit margin improved by 2.5 percentage points year-on-year, driven by a higher proportion of high-margin product revenue [1] - The company effectively controlled expenses, with the combined expense ratio (sales, management, and R&D) decreasing by 8.7 percentage points year-on-year [1] Future Outlook - With the accelerated market penetration of low-concentration atropine, the company is expected to see accelerated growth in performance and sustained improvement in profitability [1] - Using a discounted cash flow valuation method, the estimated fair market value of the company is projected to be 19.675 billion yuan, corresponding to a target price of 80.19 yuan per share, maintaining a "buy" rating [1]

Group 1 - The core point of the article is that Xingqi Eye Medicine announced its cash dividend distribution plan for the first half of 2025, which is 7.00 yuan per 10 shares (including tax) [1] - The record date for the dividend distribution is set for September 23, 2025 [1] - The ex-dividend date is scheduled for September 24, 2025 [1]

2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）2025年半年度权益分派方 案已获2025年9月15日召开的2025年第二次临时股东大会审议通过，现将权益分 派事宜公告如下： 一、股东会审议通过权益分派分配方案情况 1、公司 2025 年第二次临时股东大会审议通过的 2025 年半年度权益分派方 案为：以现有总股本 245,348,945 股为基数，向全体股东每 10 股派发现金红利 7.00 元（含税），共分配现金红利 171,744,261.50 元（含税）；不以公积金转增 股本，不送红股；剩余未分配利润结转未来分配。若在分配方案实施前，公司总 股本由于股份回购注销、增发新股、股权激励行权、可转债转股等原因发生变动 的，将按照"现金分红总额固定不变"的原则，相应调整分配。 2、自权益分派方案披露至实施期间公司股本总额未发生变化。 3、本次实施的分配方案与 2025 年第二次临时股东大会审议的分配方案一致。 4、本次分配方案的实施，距离股东会审议通过的时间未超过两个月。 证券代码 ...

Group 1 - The company announced the convening of the sixth fourth employee representative assembly on September 15, 2025 [2] - The assembly approved the election of Mr. Yang Qiang as the employee representative director of the fifth board of directors [2] - Mr. Yang's term will last from the date of approval by the employee representative assembly until the end of the fifth board's term [2]

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-043 沈阳兴齐眼药股份有限公司 关于选举第五届董事会职工代表董事的公告 1 职工代表董事简历 杨强先生，1984 年 10 月出生，中国国籍，无境外永久居留权，毕业于沈阳 药科大学药物制剂专业，博士学位，2021 年获得辽宁省总工会颁发的"辽宁五 一劳动奖章"。杨强先生 2012 年加入公司，曾任公司研发中心工艺研究室主任， 现任公司职工代表董事、副总经理、研发中心负责人。 截至本公告披露日，杨强先生持有公司 308，974 股股票，与公司控股股东、 实际控制人、持股 5%以上的股东及董事、高级管理人员不存在关联关系；符合 《公司法》相关规定，从未受过中国证监会及其他有关部门的处罚和证券交易所 惩戒，不存在《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司 规范运作》第 3.2.3、3.2.4 条所规定的情形，不属于失信被执行人。 公司于2025年9月15日召开第六届第四次职工代表大会，经全体与会职工代 表审议，同意选举杨强先生（简历详见附件）担任公司第五届董事会职工代表董 事，任期自本次职工代表大会审议通过之日起至第五届董事会届满 ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 关于沈阳兴齐眼药股份有限公司 致：沈阳兴齐眼药股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》（以下简称 "《公司法》"）以及中国证券监督管理委员会颁布的《上市公司股东会规则》 （以下简称"《股东会规则》"）的规定，北京市竞天公诚律师事务所（以下 简称"本所"）指派律师出席了沈阳兴齐眼药股份有限公司（以下简称"公 司"）2025年第二次临时股东大会（以下简称"本次股东大会"），并就本次 股东大会的有关事宜出具本法律意见书。 本所在此同意，公司可以将本法律意见书作为本次股东大会公告的法定文 件，随其他公告文件一并提交深圳证券交易所予以审核公告。 本所律师根据《股东会规则》第六条的要求，按照律师行业公认的业务标 准、道德规范和勤勉尽责精神，对本次股东大会召集和召开的有关事实及公司 提供的文件进行了核查和验证，现出具法律意见如下： 一、本次股东大会的召集、召开程序 1、本次股东大会的召集程序 本次股东大会由公司董事会根据2 ...